Proteins of Resistence and Drug Resistence in Ovarian Carcinoma Patients
Authors:
I. Sedláková 1; J. Laco 2; J. Tošner 1; K. Caltová 3; M. Červinka 3; A. Řezáč 1; J. Špaček 1; P. Škapinec 1
Authors‘ workplace:
Porodnická a gynekologická klinika LF UK a Fakultní nemocnice Hradec Králové, přednosta doc. MUDr. Jindřich Tošner, CSc.
1; Fingerlandův ústav patologie Fakultní nemocnice Hradec Králové, přednosta prof. MUDr. Aleš Ryška, PhD.
2; Ústav biologie a lékařské genetiky Lékařské fakulty Hradec Králové UK v Praze, přednosta prof. MUDr. RNDr. Miroslav Červinka, CSc.
3
Published in:
Klin Onkol 2012; 25(6): 457-463
Category:
Original Articles
Práce byla podpořena grantem IGA MZ ČR NS 9737-3.
Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.
Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do bi omedicínských časopisů.
Overview
Background:
To evaluate the correlation of resistance proteins LRP (Lung Resistance Protein), Pgp (P-glycoprotein), MRP (Multidrug Resistance-Associated Protein), MRP3 a MRP5 with stage, grade and histological type. To asses correlation of these resistance proteins with drug resistance/drug sensitivity in vitro by means of the MTT assay in ovarian cancer patients. To find the clinical outcome of these data.
Patients and Methods:
64 women with epithelial ovarian cancer who underwent primary surgery in 2006–2010 had specimens stained with imunohistochemistry for LRP, MRP, MRP3, MRP5 and Pgp and MTT assay (MTT-(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide).
Results:
Patients with late ovarian cancer had a higher Pgp, MRP, MRP3 and MRP5 level compared to ovarian cancer patients with early stage ovarian cancer. No correlation of resistance proteins with grading was found. Patients with high Pgp and MRP expression had significantly shorter progression-free survival. Patients with drug resistance in vitro by means of the MTT assay had higher Pgp and MRP expression.
Conclusion:
P-glycoprotein and MRP may be useful predictor for outcome of primary chemotherapy in patients with ovarian cancer.
Key words:
ovarian cancer – p170-glycoprotein – Lrp-Lung resistance protein – MRP1 protein – Drug Resistance – MTT test
Sources
1. Cibula D, Petruželka L et al. Onkogynekologie. Praha: Grada Publishing 2009.
2. Fruehauf PJ, Alberts DS. In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 2005; 23(15): 3641–3643.
3. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott-Raven 2001: 597–632.
4. Nosková V, Hajdúch M, Mihál V et al. Mechanismy mnohočetné lékové rezistence a jejich význam pro klinickou praxi I. typická MDR. Klin Onkol 2000; 13(2): 4–9.
5. Václavíková R, Hubáčková M, Kubala E et al. Exprese genu mnohočetné lékové rezistence 1 (MDR1) a její význam v rozvoji a terapii karcinomu prsu. Klin Onkol 2007; 20(3): 253–259.
6. Zhang JT. The multi-structural feature of the multidrug resistance gene product P-glycoprotein: implications for its mechanism of action (hypothesis). Mol Membr Biol 2001; 18(2): 145–152.
7. Kuwano M, Uchiumi T, Hayakawa H et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci 2003; 94(1): 9–14.
8. Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barier. Adv Drug Deliv Rev 1999; 36(2–3): 179–194.
9. Larkin A, O’Driscoll L, Kennedy S et al. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer 2004; 112(2): 286–294.
10. Schneider J, Gonzales-Roces S, Pollán M et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy. Breast Cancer Res 2001; 3(3): 183–191.
11. Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates with ER and with high Ki67 expression but fails to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat 1995; 36(1): 61–69.
12. Izquirerdo MA, van der Zee AG, Vermorken JB et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87(16): 1230–1237.
13. Goff BA, Paley PJ, Greer BE et al. Evaluation of chemoresistance markers in woman with epithelial ovarian carcinoma. Gynecol Oncol 2001; 81(1): 18–24.
14. Arts HJ, Katsaros D, de Vries EG et al. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated proetin 2, and lung resistance protein as prognostic factors in ovarian carcinoma. Clin Cancer Res 1999; 5(10): 2798–2805.
15. Materna V, Pleger J, Hoffman U et al. RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response. Gynecol Oncol 2004; 94(1): 152–160.
16. Sedláková I, Tošner J, Řezáč A et al. Rezistence/sensitivita in vitro u pacientek s karcinomem ovaria. Česk Gynekol 2011; 76(3): 184–189.
17. Xing H, Wang S, Weng D et al. Knock-down of P-glycoprotein reverses taxol resistance in ovarian cancer multicellular spheroids. Oncol Rep 200; 17(1): 117–122.
18. Kamazawa S, Kigawa J, Kanamori Y et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002; 86(2): 171–176.
19. Scheffer GL, Kool M, Heijn M et al. Specific detection of multidrug resistance proteins MRP, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res 2000; 60(18): 5269–5277.
20. Odening KE, Rutz R, Laufs S et al. Enhanced complement resistance in drug-selected P-glycoprotein expressing multi-drug-resistant ovarian carcinoma cells. Clin Exp Immunol 2008; 155(2): 239–248.
21. Kavallaris M, Leary JA, Barrett JA et al. MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett 1996; 102(1–2): 7–16.
22. Baekelandt MM, Holm R, Nesland JM et al. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000; 20(2B): 1061–1067.
23. Raspollini MR, Amunni G, Villanucci A et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer 2004; 14(5): 815–823.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2012 Issue 6
Most read in this issue
- Liver Function Assessment in Oncology Practice
- Cost Analysis of XELOX and FOLFOX-4 Chemotherapy Regimens for Colorectal Carcinoma
- Incidentally Discovered White Subcupsular Liver Nodules during Laparoscopic Surgery: Biliary Hamartoma and Peribiliary Gland Hamartoma
- A Case Report: Patient with Advanced Ovarial Tumour and Supporting Care